RXST:NSD-Rxsight Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 52.77

Change

0.00 (0.00)%

Market Cap

USD 1.91B

Volume

0.27M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 49.24B
ALGN Align Technology Inc

N/A

USD 20.45B
SWAV Shockwave Medical Inc

N/A

USD 12.34B
BRKR Bruker Corporation

N/A

USD 11.77B
PODD Insulet Corporation

N/A

USD 11.64B
MASI Masimo Corporation

N/A

USD 7.20B
IRTC iRhythm Technologies Inc

N/A

USD 3.48B
AXNX Axonics Modulation Technologie..

N/A

USD 3.44B
TMDX TransMedics Group Inc

N/A

USD 3.02B
LIVN LivaNova PLC

N/A

USD 3.00B

ETFs Containing RXST

FDLS Northern Lights Fund Trus.. 1.03 % 0.00 %

N/A

USD 0.09B
FYC First Trust Small Cap Gro.. 0.00 % 0.70 %

N/A

USD 0.26B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

N/A

USD 0.25B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.88% 89% A- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.88% 89% A- 88% B+
Trailing 12 Months  
Capital Gain 194.80% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 194.80% 97% N/A 98% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 59.98% 90% A- 92% A
Dividend Return 59.98% 90% A- 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 85.53% 36% F 18% F
Risk Adjusted Return 70.12% 97% N/A 90% A-
Market Capitalization 1.91B 87% B+ 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.